ADXS - Ayala Pharmaceuticals, Inc.

0.25
0.250   100.000%

Share volume: 0
Last Updated: 01-05-2022
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 0%
Dept financing 40%
Liquidity 55%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
-95.97%
2 Year
-97.65%
Key data
Stock price
$0.25
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$7.99
52 WEEK RANGE
$0.00 - $0.64
52 WEEK CHANGE
-$95.97
MARKET CAP 
4.015 M
YIELD 
N/A
SHARES OUTSTANDING 
49.300 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Ken Berlin
Region: US
Website: advaxis.com
Employees: 20
IPO year: 2011
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Advaxis, Inc. focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer.

Recent news
loading